The “high-grade” expression distribution among molecular subtypes was as follows: luminal A 8/84 (9.5%), luminal B HER2− 16/109 (14.7%), luminal B HER2+ 5/19 (26.3%), HER2+ 0/2 (0%), and triple-negative breast cancer (TNBC) 27/39 (69.2%). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.